Abbott launches Freenome’s colorectal cancer screening test
Published . Updated .
Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.
Directly affected
- FRNM Freenome
Named in this report.
Indirectly affected
- CRDF CARDIFF ONCOLOGY INC COM
GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.
Source: MedTech Dive
Filings that name Cardiff Oncology (CRDF) around 30 Sep 2026
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “Abbott launches Freenome’s colorectal cancer screening test”
Companies mentioned with this story
- CRDF Cardiff Oncology
For “Abbott launches Freenome’s colorectal cancer screening test,” Cardiff Oncology (CRDF) is linked, with no stored direction, medium confidence. Reason on file: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Abbott launches Freenome’s colorectal cancer screening test.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Abbott launches Freenome’s colorectal cancer screening test.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Abbott launches Freenome’s colorectal cancer screening test,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “Abbott launches Freenome’s colorectal cancer screening test,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Abbott launches Freenome’s colorectal cancer screening test,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “Abbott launches Freenome’s colorectal cancer screening test” reaches Cardiff Oncology (CRDF)
“Abbott launches Freenome’s colorectal cancer screening test” (30 Sep 2026) reaches Cardiff Oncology (CRDF) through this story.
The link for Cardiff Oncology (CRDF) is this: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Also listed, Acadia Healthcare (ACHC): GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
What the saved facts support for Cardiff Oncology (CRDF)
46 out of 100
“Abbott launches Freenome’s colorectal cancer screening test” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.